Literature DB >> 28523942

Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.

Anish Babu1,2, Anupama Munshi2,3, Rajagopal Ramesh1,2,4.   

Abstract

RNA interference (RNAi) is emerging as a powerful approach in cancer treatment. siRNA is an important RNAi tool that can be designed to specifically silence the expression of genes involved in drug resistance and chemotherapeutic inactivity. Combining siRNA and other therapeutic agents can overcome the multidrug resistance (MDR) phenomenon by simultaneously silencing genes and enhancing chemotherapeutic activity. Moreover, the therapeutic efficiency of anticancer drugs can be significantly improved by additive or synergistic effects induced by siRNA and combined therapies. Co-delivery of these diverse anticancer agents, however, requires specially designed nanocarriers. This review highlights the recent trends in siRNA/anticancer drug co-delivery systems under the major categories of liposomes/lipid, polymeric and inorganic nanoplatforms. The objective is to discuss the strategies for nanocarrier-based co-delivery systems using siRNA/anticancer drug combinations, emphasizing various siRNA targets that help overcome MDR and enhance therapeutic efficiency.

Entities:  

Keywords:  Cancer therapy; chemotherapeutic; co-delivery; liposome; nanoparticle; siRNA

Mesh：

Substances：

Year:  2017        PMID： 28523942      PMCID： PMC6101010          DOI： 10.1080/03639045.2017.1313861

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN： 0363-9045            Impact factor:   3.225


  101 in total

Review 1.  RNA interference and its role in cancer therapy.

Authors:  Behzad Mansoori; Siamak Sandoghchian Shotorbani; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2014-08-10

2.  Non-Covalently Functionalized of Single-Walled Carbon Nanotubes by DSPE-PEG-PEI for SiRNA Delivery.

Authors:  King Sun Siu; Yujuan Zhang; Xiufen Zheng; James Koropatnick; Wei-Ping Min
Journal:  Methods Mol Biol       Date:  2016

3.  Niosomal delivery of 5-fluorouracil.

Authors:  A Namdeo; N K Jain
Journal:  J Microencapsul       Date:  1999 Nov-Dec       Impact factor: 3.142

4.  Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.

Authors:  Yuling Xiao; Renata Jaskula-Sztul; Alireza Javadi; Wenjin Xu; Jacob Eide; Ajitha Dammalapati; Muthusamy Kunnimalaiyaan; Herbert Chen; Shaoqin Gong
Journal:  Nanoscale       Date:  2012-11-21       Impact factor: 7.790

5.  Tumor heterogeneity and drug resistance.

Authors:  D L Dexter; J T Leith
Journal:  J Clin Oncol       Date:  1986-02       Impact factor: 44.544

Review 6.  Development of therapeutic combinations targeting major cancer signaling pathways.

Authors:  Timothy A Yap; Aurelius Omlin; Johann S de Bono
Journal:  J Clin Oncol       Date:  2013-03-18       Impact factor: 44.544

7.  Self-degrading niosomes for encapsulation of hydrophilic and hydrophobic drugs: An efficient carrier for cancer multi-drug delivery.

Authors:  Varsha Sharma; Sundaramurthy Anandhakumar; Manickam Sasidharan
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2015-07-02       Impact factor: 7.328

8.  The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

Authors:  Yogesh B Patil; Suresh K Swaminathan; Tanmoy Sadhukha; Linan Ma; Jayanth Panyam
Journal:  Biomaterials       Date:  2009-10-01       Impact factor: 12.479

9.  Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.

Authors:  Maha Saad; Olga B Garbuzenko; Tamara Minko
Journal:  Nanomedicine (Lond)       Date:  2008-12       Impact factor: 5.307

10.  Chemotherapy drug delivery from calcium phosphate nanoparticles.

Authors:  Xingguo Cheng; Liisa Kuhn
Journal:  Int J Nanomedicine       Date:  2007
View more
  11 in total

1.  Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells.

Authors:  Mina Afrashteh Nour; Fatemeh Kheradmand; Yousef Rasmi; Behzad Baradaran
Journal:  Med Oncol       Date:  2022-08-16       Impact factor: 3.738

2.  siRNA Targeting Mcl-1 Potentiates the Anticancer Activity of Andrographolide Nanosuspensions via Apoptosis in Breast Cancer Cells.

Authors:  Supusson Pengnam; Purin Charoensuksai; Boon-Ek Yingyongnarongkul; Rungnapha Saeeng; Hasan Uludağ; Prasopchai Patrojanasophon; Praneet Opanasopit; Samarwadee Plianwong
Journal:  Pharmaceutics       Date:  2022-06-03       Impact factor: 6.525

Review 3.  New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy.

Authors:  Krishan Kumar; Varsha Rani; Mohini Mishra; Ruchi Chawla
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-04-28

Review 4.  RNA-based therapies: A cog in the wheel of lung cancer defense.

Authors:  Parvez Khan; Jawed Akhtar Siddiqui; Imayavaramban Lakshmanan; Apar Kishor Ganti; Ravi Salgia; Maneesh Jain; Surinder Kumar Batra; Mohd Wasim Nasser
Journal:  Mol Cancer       Date:  2021-03-19       Impact factor: 27.401

5.  Multifunctional stimuli responsive polymer-gated iron and gold-embedded silica nano golf balls: Nanoshuttles for targeted on-demand theranostics.

Authors:  Liping Wang; Grace Jang; Deependra Kumar Ban; Vrinda Sant; Jay Seth; Sami Kazmi; Nirav Patel; Qingqing Yang; Joon Lee; Woraphong Janetanakit; Shanshan Wang; Brian P Head; Gennadi Glinsky; Ratneshwar Lal
Journal:  Bone Res       Date:  2017-12-20       Impact factor: 13.567

6.  Synergistic Effect of Doxorubicin and siRNA-Mediated Silencing of Mcl-1 Using Cationic Niosomes against 3D MCF-7 Spheroids.

Authors:  Supusson Pengnam; Samarwadee Plianwong; Prasopchai Patrojanasophon; Widchaya Radchatawedchakoon; Boon-Ek Yingyongnarongkul; Praneet Opanasopit; Purin Charoensuksai
Journal:  Pharmaceutics       Date:  2021-04-14       Impact factor: 6.321

7.  Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells.

Authors:  Qingchun Lu; Mingyang Xin; Qian Guo; Brad S Rothberg; Ana M Gamero; Ling Yang
Journal:  Noncoding RNA       Date:  2022-08-10

8.  Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.

Authors:  Jun-Yi Wu; Zhong-Xia Wang; Guang Zhang; Xian Lu; Guang-Hui Qiang; Wei Hu; An-Lai Ji; Jun-Hua Wu; Chun-Ping Jiang
Journal:  Int J Nanomedicine       Date:  2018-03-05

9.  Conjugation of Doxorubicin to siRNA Through Disulfide-based Self-immolative Linkers.

Authors:  Florian Gauthier; Jean-Rémi Bertrand; Jean-Jacques Vasseur; Christelle Dupouy; Françoise Debart
Journal:  Molecules       Date:  2020-06-11       Impact factor: 4.411

10.  In-Vitro Application of Magnetic Hybrid Niosomes: Targeted siRNA-Delivery for Enhanced Breast Cancer Therapy.

Authors:  Viktor Maurer; Selin Altin; Didem Ag Seleci; Ajmal Zarinwall; Bilal Temel; Peter M Vogt; Sarah Strauß; Frank Stahl; Thomas Scheper; Vesna Bucan; Georg Garnweitner
Journal:  Pharmaceutics       Date:  2021-03-16       Impact factor: 6.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.